Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor ...

"Imugene announces Phase Ib azer-cel efficacy data" was originally created and published by Clinical Trials Arena, a ...

Innovent's Pecondle, a recombinant anti-interleukin-23p19 subunit, receives China NMPA approval to treat moderate-to-severe plaque psoriasis: San Francisco Monday, December 1, 202 ...

A study published in The New England Journal of Medicine has reported that the oral peptide icotrokinra, a selective ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. This iPhone 16 rumor hub ...

Using human iPSC-derived kidney organoids, researchers showed that NPHP1 deficiency triggers abnormal Hippo signaling that ...

A simple blood test analysed by artificial intelligence could revolutionise early detection of primary vitreoretinal lymphoma ...

Imugene Ltd (ASX:IMU, OTC:IUGNF) has reported another uplift in efficacy data from its Phase 1b trial of azer-cel, its allogeneic, off-the-shelf CD19 ...

Sun Pharma introduces Ilumya in India for treatment of moderate-to-severe plaque psoriasis: Our Bureau, Mumbai Tuesday, December 2, 2025, 14:45 Hrs [IST] Sun Pharma has announced ...

What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who ...

MoonLake Immunotherapeutics (MLTX) offers strong investment potential with key clinical trials and upcoming FDA milestones. See more analysis here.

New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced ...